World Leading Small Nucleic Acid Drug CDMO Service Supplier
Hitston Ltd. (abbreviated as "Hitston") is a world leading small nucleic acid drug CDMO service platform jointly established by HitGen Inc. (stock code: 688222.SH) and Easton Biopharmaceuticals (stock code: 688513.SH), specializing in providing pharmaceutical companies and research institutions with full value chain solutions from preclinical to commercial production.
Based on a 2000㎡ oligonucleotide GMP facility, 1000㎡ quality control laboratory, and HitGen's professional R&D laboratories, Hitston has achieved gram-to-kilogram-scale API production for IND applications, clinical Phase I-III, and early commercialization stages, with a total investment of nearly $15 Million, covering global demand.